David Taylor, medical director and emergency doctor for Riverwood. Adverse effects included hallucinations, vomiting, tremors, anxiety, dizziness, confusion, and loss of consciousness. In California, where medical and recreational cannabis is legal, products containing delta-8 THC are available at gas stations and tobacconists, as well as in dispensaries, he says. The FDA is also concerned that delta-8 THC products may expose consumers to much higher levels of the substance than those found naturally in raw hemp and cannabis extracts.
Delta-8 tetrahydrocannabinol (THC) is one of more than 100 compounds known as cannabinoids found in the cannabis plant. It's important for consumers to know that delta-8 THC products have not been evaluated or approved by the FDA for safe use in any context. In addition, the FDA is concerned about the proliferation of products that contain delta-8 THC and that are marketed for therapeutic or medical purposes, even if they have not been approved by the FDA. The natural amount of delta-8 THC in hemp is very low and additional chemicals are needed to convert other hemp cannabinoids, such as CBD, into delta-8 (i.
Because the natural amount of delta-8 in hemp is very low, chemicals are needed to convert other hemp cannabinoids, such as CBD, into delta-8 (i. Exposures do not necessarily represent poisoning or overdose and the AAPCC cannot fully verify their accuracy.) of each report. It is estimated that delta-8 THC is between 50 and 75% more psychoactive than delta-9, but it only occurs naturally at very low levels in the cannabis plant, according to the CDC. It is similar to delta-9 THC, the psychoactive compound that is primarily responsible for the euphoria that people experience with marijuana.
The Food and Drug Administration warns the public that cannabis products containing delta-8 THC can pose serious health risks to consumers. The FDA is aware of the growing concern surrounding the delta-8 THC products currently being sold online and in stores. In addition, the FDA is concerned about the proliferation of products that contain delta-8 THC and that are marketed for therapeutic or medical uses without approval, a marketing practice that the agency describes as misleading, violates federal law and puts consumers at risk. The FDA is actively working with federal and state partners to further address concerns related to these products and to monitor the market for complaints about products, adverse events, and other emerging products derived from cannabis that may be a cause for concern.
Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels after weight loss. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the enzymatic system that metabolizes liver microsomal drugs in mice.